|
|
|
|
|
|
|
|
|
|
|
|
Ch. 373 2002 LAWS OF MARYLAND
|
|
|
|
|
|
|
(G) "PRACTICE MEDICAL RADIATION TECHNOLOGY" MEANS TO USE IONIZING
RADIATION TO:
(1) DEMONSTRATE PORTIONS OF THE HUMAN BODY TO ASSIST IN THE
DIAGNOSIS OR LOCALIZATION OF DISEASE OR INJURY;
(2) PERFORM TUMOR LOCALIZATION RADIOGRAPHY; OR
(3) APPLY THERAPEUTIC DOSES OF RADIATION FOR TREATMENT OF
DISEASE.
(H) "PRACTICE NUCLEAR MEDICINE TECHNOLOGY" MEANS TO:
(1) PREPARE AND ADMINISTER RADIOPHARMACEUTICALS TO HUMAN
BEINGS; OR
(2) CONDUCT IN VIVO DETECTION AND MEASUREMENT OF
RADIOACTIVITY FOR MEDICAL PURPOSES TO ASSIST IN THE DIAGNOSIS AND
TREATMENT OF DISEASE OR INJURY.
(I) "PRACTICE RADIATION ONCOLOGY/THERAPY TECHNOLOGY" MEANS TO
PERFORM TUMOR LOCALIZATION RADIOGRAPHY AND APPLY THERAPEUTIC DOSES
OF RADIATION FOR THE TREATMENT OF DISEASE OR INJURY.
(J) "SUPERVISION" MEANS THE RESPONSIBILITY OF A LICENSED PHYSICIAN
TO EXERCISE ON-SITE OR IMMEDIATELY AVAILABLE DIRECTION FOR A CERTIFIED
MEDICAL RADIATION TECHNOLOGIST OR A CERTIFIED NUCLEAR MEDICINE
TECHNOLOGIST.
14-5B-02.
THIS SUBTITLE DOES NOT LIMIT THE RIGHT OF AN INDIVIDUAL TO PRACTICE A
HEALTH OCCUPATION THAT THE INDIVIDUAL IS AUTHORIZED TO PRACTICE UNDER
THIS ARTICLE.
14-5B-03.
THE BOARD SHALL ADOPT REGULATIONS FOR THE CERTIFICATION OF
RADIATION ONCOLOGY/THERAPY TECHNOLOGISTS, MEDICAL RADIATION
TECHNOLOGISTS, AND NUCLEAR MEDICINE TECHNOLOGISTS AND FOR THE
PRACTICE OF RADIATION ONCOLOGY/THERAPY TECHNOLOGY, MEDICAL RADIATION
TECHNOLOGY, AND NUCLEAR MEDICINE TECHNOLOGY.
14-5B-04.
(A) (1) THE BOARD SHALL SET REASONABLE FEES FOR THE ISSUANCE OF
AND RENEWAL OF CERTIFICATES AND OTHER SERVICES IT PROVIDES TO RADIATION
ONCOLOGY/THERAPY TECHNOLOGISTS, MEDICAL RADIATION TECHNOLOGISTS, AND
NUCLEAR MEDICINE TECHNOLOGISTS.
(2) THE FEES CHARGED SHALL BE SET SO AS TO PRODUCE FUNDS TO
APPROXIMATE THE COST OF MAINTAINING THE CERTIFICATION PROGRAM AND THE
OTHER SERVICES PROVIDED TO RADIATION ONCOLOGY/THERAPY TECHNOLOGISTS,
MEDICAL RADIATION TECHNOLOGISTS, AND NUCLEAR MEDICINE TECHNOLOGISTS.
|
|
|
|
|
|
|
|
- 2974 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|